News – Page 16 – Alligator Bioscience

2022-02-112022-05-17

Regulatory

Alligator Bioscience AB: Year End report January–December 2021

OPTIMIZE-1 Phase II – On Track and Moving Forward “During the fourth quarter 2021, Alligator reached several key milestones in our pre-clini ...

2022-02-042022-03-23

LUND (Sweden) – February 4, 2022 – Alligator Bioscience will host a conference call (in English) for investors, analysts and media on Friday ...

2022-02-01

Lund, Sweden, February 1, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) Alligator Bioscience (Nasdaq Stockholm: ATORX), today announ ...

2022-01-20

Lund, Sweden, January 20, 2021– Alligator Bioscience (Nasdaq Stockholm: ATORX) Alligator Bioscience (Nasdaq Stockholm: ATORX), announces tod ...

2022-01-19

Lund, Sweden, January 19, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the initiation a sponsored research collabor ...

2022-01-18

Lund, Sweden, January 18, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going OPTIMIZE-1 clinica ...

2022-01-07

Lund, Sweden, January 7, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Søren Bregenholt, Chief Executive Office ...

2021-12-30

Regulatory

During December 2021, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the completion of ...

2021-12-16

Alligator Bioscience AB (publ)’s ("Alligator" or the “Company") rights issue has now been registered with the Swedish Companies ...